Free Trial
NASDAQ:TRML

Tourmaline Bio (TRML) Stock Price, News & Analysis

Tourmaline Bio logo
$19.77 +1.02 (+5.44%)
Closing price 04:00 PM Eastern
Extended Trading
$19.88 +0.11 (+0.53%)
As of 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tourmaline Bio Stock (NASDAQ:TRML)

Key Stats

Today's Range
$18.32
$20.27
50-Day Range
$15.11
$19.90
52-Week Range
$11.56
$29.79
Volume
246,369 shs
Average Volume
148,493 shs
Market Capitalization
$507.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.33
Consensus Rating
Buy

Company Overview

Tourmaline Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

TRML MarketRank™: 

Tourmaline Bio scored higher than 38% of companies evaluated by MarketBeat, and ranked 715th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tourmaline Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Tourmaline Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tourmaline Bio is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tourmaline Bio is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tourmaline Bio has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Tourmaline Bio's valuation and earnings.
  • Percentage of Shares Shorted

    17.96% of the float of Tourmaline Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Tourmaline Bio has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Tourmaline Bio has recently increased by 1.03%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Tourmaline Bio does not currently pay a dividend.

  • Dividend Growth

    Tourmaline Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.96% of the float of Tourmaline Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Tourmaline Bio has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Tourmaline Bio has recently increased by 1.03%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Tourmaline Bio has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Tourmaline Bio this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for TRML on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tourmaline Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tourmaline Bio's insider trading history.
Receive TRML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter.

TRML Stock News Headlines

Tourmaline Bio Inc News (TRML) - Investing.com
The Private Market Surge Is Coming in 2025
The most lucrative investment opportunities are reserved for a select category of investor. They're private. They're quiet. And they're often available exclusively to accredited investors operating outside the noise of the public markets. We're talking about off-market placements, early venture deals, private credit, and pre-IPO shares—the kind of plays that can generate outsized gains before Wall Street catches wind. Here's the reality: having access is only the beginning. These deals can be opaque, rushed, and filled with hidden risk. That's why we created something exclusively for investors like you—the 2025 Accredited Investor Playbook.
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar
See More Headlines

TRML Stock Analysis - Frequently Asked Questions

Tourmaline Bio's stock was trading at $20.28 on January 1st, 2025. Since then, TRML stock has decreased by 2.5% and is now trading at $19.77.

Tourmaline Bio, Inc. (NASDAQ:TRML) announced its quarterly earnings results on Friday, May, 2nd. The company reported ($0.89) earnings per share for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02.

Top institutional investors of Tourmaline Bio include Wesbanco Bank Inc. (0.10%). Insiders that own company stock include Mark Mcdade, Parvinder Thiara, Aaron Kantoff and Sandeep Chidambar Kulkarni.
View institutional ownership trends
.

Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
5/02/2025
Today
7/25/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRML
Previous Symbol
NASDAQ:TRML
CIK
1827506
Web
N/A
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

High Price Target
$70.00
Low Price Target
$25.00
Potential Upside/Downside
+149.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.21 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.75%
Return on Assets
-26.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
33.87
Quick Ratio
33.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.71 per share
Price / Book
1.69

Miscellaneous

Outstanding Shares
25,680,000
Free Float
22,346,000
Market Cap
$507.69 million
Optionable
Optionable
Beta
2.00
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:TRML) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners